No Data
10x Genomics Unveils Innovation Roadmap at AGBT General Meeting, Advancing Leadership in Large-Scale Single Cell and Spatial Analysis
10x Genomics to Participate in the 45th Annual TD Cowen Health Care Conference
10x Genomics Is Maintained at Overweight by Morgan Stanley
Morgan Stanley Maintains 10x Genomics(TXG.US) With Buy Rating, Cuts Target Price to $26
A Quick Look at Today's Ratings for 10x Genomics(TXG.US), With a Forecast Between $12 to $18
Barclays Maintains Overweight on 10x Genomics, Lowers Price Target to $15
